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Conclusions: Using this multivariate prediction model a 
reliable prediction of the probability of severe fibrosis in the 
breast can be made. The dose-volume parameters can be 
used to further optimize the radiotherapy planning, in order 
to reduce the incidence of this complication.  
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Purpose/Objective: Accelerated partial breast irradiation 
(APBI) has been studied as an alternative to whole breast 
irradiation for patients with low risk of local recurrence. 
Several studies on postoperative external beam APBI showed 
variable results concerning toxicity and cosmetic outcome. 
Unfavourable results are associated with large treatment 
volumes. Large inter-observer variability in defining the 
tumor bed for postoperative irradiation has been 
demonstrated, resulting in larger irradiated volumes. (1) 
By shifting from postoperative to preoperative radiotherapy 
more accurate target delineation can be performed. (2) 
Furthermore, the breast tissue that received the highest 
radiation dose is surgically removed. As a result, limited 
fibrosis and a good cosmetic outcome is expected. In 
addition, preoperative APBI gives the possibility for 
translational research by assessing tumor response.  
The main objective of Preoperative Accelerated Partial 
Breast Irradiation (PAPBI) trial (ClinicalTrials.gov, 
CT01024582) is to investigate the impact on local control, 
breast fibrosis and cosmesis. In this interim-analysis we 
present the results for the first 70 patients.  
Materials and Methods: In our ongoing phase II, multi-center 
trial women aged ≥ 60 years with an invasive, unifocal ≤ 3 cm 
on MRI, (non-lobular) adenocarcinoma of the breast and a 
negative sentinel node were treated with PAPBI (40 Gy in 10 
fractions over 2 weeks). Six weeks after radiotherapy a wide 
local excision was performed. 
Results: 70 patients with a median follow-up of 21 months 
(3-43 months) were evaluated. Patient characteristics are 
shown in table 1. The mean irradiated (planning target) 
volume was 122 cc (range 13-263).  
The overall postoperative infection rate was 11% and the 
postoperative hematoma rate 5,7%. At 1, 2 and 3 years of 
follow-up no or mild fibrosis was present in respectively 86%, 
97% and 100% of the patients. Fibrosis, when present, was 
only found in a small volume of the breast. The global 
cosmetic outcome scored by the physician was good to 
excellent in 77% at 6 months to 100% at 3 years. (figure 1) 
The majority of the Dutch patients was satisfied to very 
satisfied with the cosmetic result; 81%, 86%, 80% and 79% 
after respectively 0.5,1,2 and 3 years.  
In three patients an ipsilateral tumor recurrence (IBTR) was 
diagnosed; in one patient the IBTR was diagnosed at the skin 
entry of the biopsy tract after 12 months; one patient was 
diagnosed with an IBTR in another quadrant of the breast 
after 26 months; one patient was diagnosed with an IBTR 
after 36 months at the skin entry of the biopsy tract. 
 
 
Table 1: patient characteristics 
 
 
Conclusions: The first results of the PAPBI trial show low 
complication rates, limited fibrosis in a small volume and 
good to excellent cosmetic outcome. Fibrosis of the breast 
and cosmetic outcome scored by the physician improve over 
time. In three patients an IBTR was diagnosed. In selected 
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patients, preoperative radiotherapy appears to be a good 
option for breast conserving therapy.  
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Purpose/Objective: There is a strong inverse association 
between the proliferation indices of early- and late-
responding normal tissues and their sensitivity to 
radiotherapy fraction size. The aim of this study is to test for 
association between Ki67 index and the fractionation 
sensitivity of breast cancer. The hypothesis is that tumours 
with high Ki67 indices are relatively insensitive to fraction 
size and over-represented in tumours relapsing after 
hypofractionated radiotherapy.  
Materials and Methods: Between 1986 and 2003, the START-
P and START-A trials each tested 2 test dose levels of a 13-
fraction regimen (3.0 vs 3.3 Gy & 3.0 vs 3.2 Gy fractions, 
respectively) in 5 weeks against 25 fractions of 2.0 Gy 
following primary surgery for early breast cancer. Primary 
tumour blocks of patients with local tumour relapse were 
collected for immunohistochemistry (IHC) for Ki67, HER2, ER, 
PR, CK5/6, EGFR, Geminin, Cyclin A, ATM, BRCA, PTEN and 
p53. A novel image-processing algorithm was developed to 
enable in silico alignment of serial tumor sections on a pixel-
level and subsequent automated Ki67 scoring. For the initial 
Ki67 assessment all relapsed patients in the test arms were 
grouped together.  
Results: From a total of 3646 patients entered into the 
START-P & -A trials, 261 local tumour relapses were recorded 
at a median follow up of 8.4 years (range 0.9-17.5) and 7.2 
years (range 0.7-11.9), respectively. Blocks from 213 patients 
were recovered, of which 181 were evaluable by IHC. There 
was no significant difference in proliferation between 
tumours relapsing after conventional and hypofractionated 
radiotherapy, with mean Ki67 scores of 7.63 (95%CI: 5.06-
11.5) and 5.33 (95CI%: 3.86-7.35), respectively. There was a 
positive correlation between Ki67 and Geminin scores 
(r=0.43, 95%CI 0.30-0.54, p<0.0001). The ongoing automated 
Ki67 scoring done in 41 patients so far has shown a high 
degree of correlation with manual scoring (r=0.76, 95%CI 
0.60-0.6, p<0.0001). Based on unsupervised hierarchical 
clustering analysisof biomarker expression (binarised data) 
patients were grouped mainly intoER/PR+, CK5/6 & EGFR+ 
and Ki67 high expressors, recapitulating known breastcancer 
subtypes. However, based on this 12-biomarker profile, a 
subgroup of patients enriched for recurrences in the different 
dose fractionation schedules cannot be identified. 
Conclusions: An association between proliferative indices 
and fractionation sensitivity in breast tumours has not been 
demonstrated in the 2 trials analysed together, and adjusted 
analyses of any imbalances in tumour characteristics between 
trials will be presented.  
   
 
Symposium: Advanced technology assessment: Economic 
evaluation of radiotherapy: Different approaches 
converging to a same answer?  
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Radiotherapy is an essential part of cancer care. Successive 
studies have shown radiotherapy to be inexpensive and cost-
effective. These studies are difficult to undertake and may 
not be applicable in different countries because of variations 
in work practices, wages and capital costs. A population-
based model of radiotherapy demand and benefits could 
provide an estimate cost effectiveness if it was coupled to 
cost data. It could be updated simply by adding new cost or 
epidemiological data. 
We have developed a model of every indication for 
radiotherapy that has allowed us to estimate that 48% of 
cancer cases in a Australian require radiotherapy at least 
once (http://tinyurl.com/pwkua34). It is possible to adapt 
the model to other countries by substituting the relevant 
proportions of cancer types and even stages for that country. 
The model has been expanded to estimate the number of 
fractions per indication and thus an average of 18 fractions is 
needed per course. We have also estimated the survival and 
local control benefit of radiotherapy at 5 years by tumour 
type. Using Markov modelling it is possible to calculate the 
number of Life Years Gained and thus we can calculate a 
survival benefit per fraction. By costing fractions in different 
countries it will be possible to estimate the cost per life year 
gained.  
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Europe is characterized by its highly heterogeneous 
landscape with different cultures, traditions and languages. 
In the context of cancer care as well, large differences are 
observed in cancer incidence and survival, in economic 
aspects and available resources, in organization and funding 
of health care. Cost accounting and economic evaluation 
models should be developed that allow grasping this 
heterogeneity. 
The ESTRO Health Economics in Radiation Oncology (HERO) 
project wants to provide a blueprint of the European 
radiotherapy landscape from an economical perspective. The 
aim is to support the individual European countries and their 
national radiotherapy societies in developing and sustaining 
an optimal radiotherapy service, in line with evidence-based 
